Trial Profile
A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 29 Oct 2021 Status changed from recruiting to active, no longer recruiting.